Drug Trial Radar · NCT03468426
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
252
Actual
Start
Jul 5, 2018
Primary completion
Jul 31, 2024
Study completion Sep 12, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab. BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor). The purpose of the first part of the study was to find out the highest dose of the BI 836880 that the participants can tolerate in combination with BI 754091. After the best dose of BI 836880 for the combination with ezabenlimab was found, it is used in the second part of the study. The purpose of the second part is to see whether the combination of BI 836880 and BI 754091 is able to make tumours shrink. The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of BI 836880 and ezabenlimab every 3 weeks. The doctors also regularly check the general health of the participants.
Conditions
- Non-squamous, Non-Small-Cell Lung Cancer
- Neoplasms
Interventions
BI 836880Drug
BI 836880 as an intravenous infusion on day 1 of each 3-week cycle.
EzabenlimabDrug
240 mg Ezabenlimab (BI 754091) as an intravenous infusion on day 1 of each 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Number of Patients With Dose Limiting Toxicity (DLT) Within the First Cycle of TreatmentTime frame: The first treatment cycle, up to 21 days.
- Part 2 - Objective Response (OR)Time frame: Up to 778 days.
Locations
43 sites in 12 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Beverly Hills Cancer Center
Beverly Hills, California
Winship Cancer Institute
Atlanta, Georgia
Dana-Farber Cancer Institute
Boston, Massachusetts
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists, PC
Fairfax, Virginia
Royal North Shore Hospital-St Leonards-20807
St Leonards, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Peninsula & South Eastern Oncology Group
Frankston, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
CTR Georges-François Leclerc
Dijon, France
HOP Timone
Marseille, France
INS Curie
Paris, France
CTR Eugène Marquis
Rennes, France
HOP Nord Laennec
Saint-Herblain, France
HOP Civil
Strasbourg, France
Universitätsklinikum Augsburg
Augsburg, Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
Universitätsklinikum Regensburg
Regensburg, Germany
Queen Mary Hospital
Hong Kong, Hong Kong
University Clinical Center, Gdansk
Gdansk, Poland
Mandziuk Slawomir Specialist Medical Practice
Lublin, Poland
European Health Center Otwock
Otwock, Poland
MED POLONIA SP Z O O, Clinical Trials Department,Poznan
Poznan, Poland
Dom Lekarski S.A.
Szczecin, Poland
JSC "Group of Companies "Medsi"
Moscow, Russia
SBHI "Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncological)"
Saint Petersburg, Russia
State Budget Healthcare Institution "Volgograd Regional Clinical Oncology Dispensary"
Volgograd, Russia
Seoul National University Bundang Hospital
Seongnam, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Universitari Vall D Hebron
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Clinico Universitario De Valencia
Valencia, Spain
NCKUH
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council
Dnipropetrovks, Ukraine
Kyiv City Clinical Oncological Center
Kyiv, Ukraine
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.